EUVIMEDEUVIMED entdecken
Crossref

Metformin Attenuates ox‐LDL‐Induced Macrophage Senescence and Inflammation via NR4A1‐Mediated Mitophagy Regulation

Luling Li, Xiuting Huang, Pei Li iD

Basic & Clinical Pharmacology & Toxicology · 2026

DOI: 10.1111/bcpt.70188 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2026. Verfasst von Luling Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Capital Medical University Affiliated Beijing Chao-Yang Hospital, Beijing, China. Hauptthemen laut MEDLINE: Metformin, Mitophagy, Macrophages, Cellular Senescence. Die Arbeit nennt 57 Literaturangaben. Gefördert von: Natural Science Foundation of Beijing Municipality, Beijing Natural Science Foundation, Beijing Municipal Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metformin alleviates oxidized low‐density lipoprotein (ox‐LDL)‐induced macrophage senescence, a key process in atherosclerosis. Our in vitro findings demonstrate that metformin suppresses ox‐LDL‐induced overexpression of the nuclear receptor NR4A1 in macrophages. This inhibition subsequently reduces excessive mitophagy, improves mitochondrial membrane potential and decreases reactive oxygen species (ROS) production. The amelioration of this mitochondrial dysfunction directly attenuated cellular senescence markers and reduced the secretion of inflammatory cytokines. Furthermore, we identified Caveolin‐1 as a critical regulator of metformin's protective effects. Overexpression of Caveolin‐1 was shown to reverse metformin‐mediated improvements in mitochondrial function. These results establish that metformin mitigates macrophage senescence by targeting the NR4A1–mitophagy pathway, with Caveolin‐1 serving as an essential modulator. This NR4A1–mitophagy axis represents a promising therapeutic target, positioning metformin as a potential candidate for slowing atherosclerosis progression by preserving mitochondrial health in macrophages.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminMitophagyMacrophagesCellular SenescenceLipoproteins, LDLNuclear Receptor Subfamily 4, Group A, Member 1Reactive Oxygen SpeciesAnimalsHumansMiceInflammationAtherosclerosisMembrane Potential, MitochondrialMitochondriaRAW 264.7 Cells

Stichwörter der Autor:innen

atherosclerosisinflammationmacrophage senescencemetforminox‐LDL

Substanzen

Metforminoxidized low density lipoproteinLipoproteins, LDLNuclear Receptor Subfamily 4, Group A, Member 1Reactive Oxygen SpeciesNr4a1 protein, mouseNR4A1 protein, human

Autor:innen und Institutionen

  • Department of Nephrology, Capital Medical University Affiliated Beijing Chao-Yang Hospital, Beijing, China.
  • Department of Geriatrics, Capital Medical University Affiliated Beijing Chao-Yang Hospital, Beijing, China.

ORCID-Profile: Pei Li

Förderung

  • Natural Science Foundation of Beijing Municipality
  • Beijing Natural Science Foundation
  • Beijing Municipal Natural Science Foundation

Zitieren

APA

Li, L., Huang, X., & Li, P. (2026). Metformin Attenuates ox‐LDL‐Induced Macrophage Senescence and Inflammation via NR4A1‐Mediated Mitophagy Regulation. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70188

Vancouver

Li L, Huang X, Li P. Metformin Attenuates ox‐LDL‐Induced Macrophage Senescence and Inflammation via NR4A1‐Mediated Mitophagy Regulation. Basic & Clinical Pharmacology & Toxicology. 2026. doi:10.1111/bcpt.70188

BibTeX
@article{Li2026,
  author = {Li, Luling and Huang, Xiuting and Li, Pei},
  title = {Metformin Attenuates ox‐LDL‐Induced Macrophage Senescence and Inflammation via NR4A1‐Mediated Mitophagy Regulation},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2026},
  doi = {10.1111/bcpt.70188}
}
Kostenlos starten →